Drug news
NICE does not recommend Imnovid/Pomalyst for treatment of Metastatic Melanoma- Celgene
The National Institute for Health Care and Clinical Excellence in the UK does not recommend Imnovid (pomalidomide) as third line treatment for Metastatic Melanoma as the Institute has not received adequate evidence of effectiveness from Celgene."Celgenes own cost effective analysis clearly demonstrated that the drug does not offer enough benefit to justify the price".
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.